GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Operating Margin %

Accelerated Pharma (Accelerated Pharma) Operating Margin % : 0.00% (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Accelerated Pharma's Operating Income for the three months ended in Mar. 2017 was $-0.41 Mil. Accelerated Pharma's Revenue for the three months ended in Mar. 2017 was $0.00 Mil. Therefore, Accelerated Pharma's Operating Margin % for the quarter that ended in Mar. 2017 was 0.00%.

The historical rank and industry rank for Accelerated Pharma's Operating Margin % or its related term are showing as below:


ACCP's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.075
* Ranked among companies with meaningful Operating Margin % only.

Accelerated Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Accelerated Pharma's Operating Income for the three months ended in Mar. 2017 was $-0.41 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2017 was $-2.10 Mil.


Accelerated Pharma Operating Margin % Historical Data

The historical data trend for Accelerated Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Operating Margin % Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Operating Margin %
- - -

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Operating Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Accelerated Pharma's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerated Pharma's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Operating Margin % falls into.



Accelerated Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Accelerated Pharma's Operating Margin % for the fiscal year that ended in Dec. 2016 is calculated as

Operating Margin %=Operating Income (A: Dec. 2016 ) / Revenue (A: Dec. 2016 )
=-3.202 / 0
= %

Accelerated Pharma's Operating Margin % for the quarter that ended in Mar. 2017 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2017 ) / Revenue (Q: Mar. 2017 )
=-0.41 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma  (NAS:ACCP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Accelerated Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines